See today's BioWorldSee today's BioWorld Asia
To read the full story, subscribe or sign in.

Kyorin in-licenses Bayer’s phase II sleep apnea drug for €85M+

Dec. 17, 2024
By Tamra Sami
Kyorin Pharmaceutical Co. Ltd. has acquired Bayer AG’s phase II obstructive sleep apnea candidate, BAY-2925976, in a deal worth €85M (US$89.3 million) plus sales-based royalties and commercial milestones.
BioWorld BioWorld Asia Deals and M&A Respiratory Small molecule Asia-Pacific Japan U.S.